



## Location, Location, Location: Treating patients with opioid use disorder in primary care

**Clinical Question: How well is opioid use disorder (OUD) managed in primary care?**

**Bottom Line: For patients with OUD, receiving opioid agonist therapy (OAT) in a primary care setting, an additional 1 in 5 patients were opioid abstinent at 46 weeks, compared to patients receiving care in a specialty care setting. Patients were also more satisfied with their treatment and physician explanations in primary care. Rates of retention were similar between groups. Provision of support and/or training was reported consistently throughout the literature**

### Evidence:

- Six randomized controlled trials (RCTs, 22-221 patients)<sup>1-6</sup> compared OAT (methadone or buprenorphine) in primary care versus specialized opioid treatment; mean follow-up 46 weeks
  - Opioid abstinence (five RCTs; 428 patients; measured by urine toxicology and/or self-report; meta-analyzed by TFP authors):
    - 55% versus 34%; Number Needed to Treat (NNT)=5
  - Retention in treatment (six RCTs; 493 patients; meta-analyzed by TFP authors):
    - 80% versus 63% specialty care; not statistically different
  - Patient satisfaction:
    - Patients were “very satisfied” more often in primary care (77% versus 38%; one RCT, 46 patients)<sup>2</sup>, more satisfied with explanations provided by their physicians (numbers not reported; one RCT, 221 patients)<sup>1</sup> and reported higher preference for primary care (70% versus 21% specialty care, 9% no preference)
    - One RCT found similar patient satisfaction between groups<sup>3</sup>
  - Withdrawal symptoms:
    - Statistically reduced from baseline, but no difference between groups<sup>3</sup>
  - Adverse events:
    - One RCT (93 patients) found no difference in emergency department visits or hospitalizations (35% versus 36% specialty care)<sup>4</sup>
    - No other adverse events reported

### Context:

- Included populations varied:
  - Patients stabilized for 6-12 months in methadone maintenance programs<sup>2,3,6</sup>

- Patients not on methadone or switching from buprenorphine<sup>1</sup>
- Patients recruited from a methadone wait-list or referred<sup>5</sup>
- Primary care providers varied, including general internists<sup>2,4,5</sup>, infectious disease-trained physicians<sup>4</sup>, and an addictions-trained physician<sup>3</sup>
- Additional supports were used:
  - Primary care settings were team-based<sup>2-6</sup>
  - Primary care providers had prior training and/or experience<sup>1,4</sup>
  - Support/training was provided<sup>1,2,4,6</sup> and 24-hour pager support<sup>2</sup>
  - Primary care settings were affiliated with or located near a specialty program<sup>1,3,5</sup>
- Over 50% of surveyed physicians reported inadequate staff, training, time and space as barriers to initiating OAT in their practice<sup>7,8</sup>

**Authors:**

Danielle Perry BScN RN, Scott Garrison MD PhD CCFP

**Disclosures:**

Authors do not have any conflicts of interest to declare.

**References:**

1. Carrieri PM, Michel L, Lions C, *et al.* PLoS One. 2014; 9(11):e112328
2. Fiellin DA, O'Connor PG, Chawarski M, *et al.* JAMA. 2001 Oct; 286(14):1724-31
3. King VL, Kidorf MS, Stoller KB, *et al.* J Subst Abuse Treat. 2006; 31(4):385-93.
4. Lucas GM, Chaudhry A, Hsu J, *et al.* Ann Intern Med. 2010; 152(11):704-11.
5. O'Connor PG, Oliveto AH, Shi JM, *et al.* Am J Med. 1998; 105(2):100-5.
6. Tuchman E, Gregory C, Simson M, *et al.* Addict Dis and Treat. 2006; 5(2):43-51.
7. DeFlavio JR, Rolin SA, Nordstrom BR, *et al.* Rural Remote Health. 2015; 15:3019. Epub 2015 Feb 4.
8. Kermack A, Flannery M, Tofighi B, *et al.* J Subst Abuse Treat. 2017 Mar; 74:1-6.